journal article·2024-06-18Open access

Engineered polysaccharides for controlling innate and adaptive immune responses

Jutaek Nam, April Kim, Kidong Kim, Jeong Hyun Moon, Juwon Baig, May Phoo, James J. Moon, Sejin Son

Nature Reviews Bioengineering· Volume 2· Issue 9

Abstract

Therapeutic interventions can be designed by exploiting the immune system's ability to initiate specific responses to various stimuli. However, specific T cell activation, which is a key target for vaccines and immunotherapies, remains challenging. Polysaccharides derived from microbial cell walls are promising immunomodulators that interact with pathogen-recognition receptors (PRRs) on dendritic cells and macrophages, triggering robust immune responses for modulating T cell function and activating effector or regulatory pathways. In this Review, we discuss the role of polysaccharides as pathogen-associated molecular patterns (PAMPs) recognized by PRRs and their immunomodulatory potential for biomedical applications. We examine the engineering aspects of polysaccharides, investigating their potential in vaccine, immunoadjuvant, immune-modulation and drug-delivery applications and highlighting their immune-activating or immune-regulatory functions. We also explore how trained immunity can be induced by polysaccharides to trigger immune responsiveness upon re-encountering pathogens. By leveraging materials engineering principles, polysaccharides can offer a platform for effective vaccines and immunotherapies against autoimmune and other diseases.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immune responses and vaccinations · Immune cells in cancer · Immune Response and Inflammation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (100+)

Show source-provided references
1. Pifferi, C., Fuentes, R. & Fernández-Tejada, A. Natural and synthetic carbohydrate-based vaccine adjuvants and their mechanisms of action. Nat. Rev. Chem. 5, 197–216 (2021).10.1038/s41570-020-00244-3 ↗
2. Padovan, E., Landmann, R. M. & De Libero, G. How pattern recognition receptor triggering influences T cell responses: a new look into the system. Trends Immunol. 28, 308–314 (2007).10.1016/j.it.2007.05.002 ↗
3. Netea, M. G., Quintin, J. & Van Der Meer, J. W. Trained immunity: a memory for innate host defense. Cell Host Microbe. 9, 355–361 (2011).10.1016/j.chom.2011.04.006 ↗
4. Novakovic, B. et al. β-glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell 167, 1354–1368.e1314 (2016).10.1016/j.cell.2016.09.034 ↗
5. Cheng, S. C. et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345, 1250684 (2014).10.1126/science.1250684 ↗
6. Akin, I. et al. Evaluation of the safety and efficacy of AdvaxTM as an adjuvant: a systematic review and meta-analysis. Adv. Med. Sci. 67, 10–17 (2022).10.1016/j.advms.2021.09.002 ↗
7. Gordon, D. L. et al. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant. Vaccine 30, 5407–5416 (2012).10.1016/j.vaccine.2012.06.009 ↗
8. Blander, J. M. & Sander, L. E. Beyond pattern recognition: five immune checkpoints for scaling the microbial threat. Nat. Rev. Immunol. 12, 215–225 (2012).10.1038/nri3167 ↗
9. Iwasaki, A. & Medzhitov, R. Regulation of adaptive immunity by the innate immune system. Science 327, 291–295 (2010).10.1126/science.1183021 ↗
10. Hancock, R. E., Nijnik, A. & Philpott, D. J. Modulating immunity as a therapy for bacterial infections. Nat. Rev. Microbiol. 10, 243–254 (2012).10.1038/nrmicro2745 ↗
11. Shekarian, T. et al. Pattern recognition receptors: immune targets to enhance cancer immunotherapy. Ann. Oncol. 28, 1756–1766 (2017).10.1093/annonc/mdx179 ↗
12. Khan, R., Shah, M. D., Shah, L., Lee, P. C. & Khan, I. Bacterial polysaccharides — a big source for prebiotics and therapeutics. Front. Nutr. 9, 1031935 (2022).10.3389/fnut.2022.1031935 ↗
13. Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373–384 (2010).10.1038/ni.1863 ↗
14. Mogensen, T. H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 22, 240–273 (2009).10.1128/CMR.00046-08 ↗
15. Zhang, X., Qi, C., Guo, Y., Zhou, W. & Zhang, Y. Toll-like receptor 4-related immunostimulatory polysaccharides: primary structure, activity relationships, and possible interaction models. Carbohydr. Polym. 149, 186–206 (2016).10.1016/j.carbpol.2016.04.097 ↗
16. Geijtenbeek, T. B. & Gringhuis, S. I. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 9, 465–479 (2009).10.1038/nri2569 ↗
17. Underhill, D. M., Rossnagle, E., Lowell, C. A. & Simmons, R. M. Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood 106, 2543–2550 (2005).10.1182/blood-2005-03-1239 ↗
18. Goodridge, H. S., Simmons, R. M. & Underhill, D. M. Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J. Immunol. 178, 3107–3115 (2007).10.4049/jimmunol.178.5.3107 ↗
19. Kashem, S. W. et al. Candida albicans morphology and dendritic cell subsets determine T helper cell differentiation. Immunity 42, 356–366 (2015).10.1016/j.immuni.2015.01.008 ↗
20. Gringhuis, S. I. et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-κB activation through Raf-1 and Syk. Nat. Immunol. 10, 203–213 (2009).10.1038/ni.1692 ↗
21. Liu, H. & Rohowsky-Kochan, C. Interleukin-27-mediated suppression of human Th17 cells is associated with activation of STAT1 and suppressor of cytokine signaling protein 1. J. Interferon Cytokine Res. 31, 459–469 (2011).10.1089/jir.2010.0115 ↗
22. Geijtenbeek, T. B. H. & Gringhuis, S. I. C-type lectin receptors in the control of T helper cell differentiation. Nat. Rev. Immunol. 16, 433–448 (2016).10.1038/nri.2016.55 ↗
23. Goodridge, H. S. et al. Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse’. Nature 472, 471–475 (2011).10.1038/nature10071 ↗
24. Gantner, B. N., Simmons, R. M., Canavera, S. J., Akira, S. & Underhill, D. M. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J. Exp. Med. 197, 1107–1117 (2003).10.1084/jem.20021787 ↗
25. Gross, O. et al. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442, 651–656 (2006).10.1038/nature04926 ↗
26. Saijo, S. et al. Dectin-2 recognition of α-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity 32, 681–691 (2010).10.1016/j.immuni.2010.05.001 ↗
27. Parsons, M. W. et al. Dectin-2 regulates the effector phase of house dust mite-elicited pulmonary inflammation independently from its role in sensitization. J. Immunol. 192, 1361–1371 (2014).10.4049/jimmunol.1301809 ↗
28. Barrett, N. A. et al. Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotrienes. J. Exp. Med. 208, 593–604 (2011).10.1084/jem.20100793 ↗
29. Barrett, N. A., Maekawa, A., Rahman, O. M., Austen, K. F. & Kanaoka, Y. Dectin-2 recognition of house dust mite triggers cysteinyl leukotriene generation by dendritic cells. J. Immunol. 182, 1119 (2009).10.4049/jimmunol.182.2.1119 ↗
30. Seifert, L. et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 532, 245–249 (2016).10.1038/nature17403 ↗
31. Lee, W. B. et al. Mincle activation enhances neutrophil migration and resistance to polymicrobial septic peritonitis. Sci. Rep. 7, 41106 (2017).10.1038/srep41106 ↗
32. Patin, E. C., Orr, S. J. & Schaible, U. E. Macrophage inducible C-type lectin as a multifunctional player in immunity. Front. Immunol. 8, 861–861 (2017).10.3389/fimmu.2017.00861 ↗
33. Li, C. et al. The Mincle/Syk/NF-κB signaling circuit is essential for maintaining the protumoral activities of tumor-associated macrophages. Cancer Immunol. Res. 8, 1004–1017 (2020).10.1158/2326-6066.CIR-19-0782 ↗
34. Werninghaus, K. et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRγ-Syk-Card9-dependent innate immune activation. J. Exp. Med. 206, 89–97 (2009).10.1084/jem.20081445 ↗
35. Wevers, B. A. et al. Fungal engagement of the C-type lectin mincle suppresses dectin-1-induced antifungal immunity. Cell Host Microbe. 15, 494–505 (2014).10.1016/j.chom.2014.03.008 ↗
36. Wüthrich, M. et al. Fonsecaea pedrosoi-induced Th17-cell differentiation in mice is fostered by Dectin-2 and suppressed by Mincle recognition. Eur. J. Immunol. 45, 2542–2552 (2015).10.1002/eji.201545591 ↗
37. Martinez-Pomares, L. The mannose receptor. J. Leukoc. Biol. 92, 1177–1186 (2012).10.1189/jlb.0512231 ↗
38. Azad, A. K., Rajaram, M. V. & Schlesinger, L. S. Exploitation of the macrophage mannose receptor (CD206) in infectious disease diagnostics and therapeutics. J. Cytol. Mol. Biol. 1, 1000003 (2014).
39. Vinogradov, S., Warren, G. & Wei, X. Macrophages associated with tumors as potential targets and therapeutic intermediates. Nanomedicine 9, 695–707 (2014).10.2217/nnm.14.13 ↗
40. Wang, H. et al. Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of shikonin/JQ1. Nano Lett. 19, 2935–2944 (2019).10.1021/acs.nanolett.9b00021 ↗
41. Preza, G. C. et al. Antigen-presenting cell candidates for HIV-1 transmission in human distal colonic mucosa defined by CD207 dendritic cells and CD209 macrophages. AIDS Res. Hum. Retroviruses 30, 241–249 (2014).10.1089/aid.2013.0145 ↗
42. Engering, A. et al. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J. Immunol. 168, 2118–2126 (2002).10.4049/jimmunol.168.5.2118 ↗
43. Hu, B. et al. Blockade of DC-SIGN+ tumor-associated macrophages reactivates antitumor immunity and improves immunotherapy in muscle-invasive bladder cancer. Cancer Res. 80, 1707–1719 (2020).10.1158/0008-5472.CAN-19-2254 ↗
44. Geijtenbeek, T. B. et al. Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100, 575–585 (2000).10.1016/S0092-8674(00)80693-5 ↗
45. Gringhuis, S. I., den Dunnen, J., Litjens, M., van der Vlist, M. & Geijtenbeek, T. B. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat. Immunol. 10, 1081–1088 (2009).10.1038/ni.1778 ↗
46. Conde, P. et al. DC-SIGN+ macrophages control the induction of transplantation tolerance. Immunity 42, 1143–1158 (2015).10.1016/j.immuni.2015.05.009 ↗
47. Raphael, I., Nalawade, S., Eagar, T. N. & Forsthuber, T. G. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74, 5–17 (2015).10.1016/j.cyto.2014.09.011 ↗
48. Acosta-Rodriguez, E. V. et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8, 639–646 (2007).10.1038/ni1467 ↗
49. Keler, T., He, L., Ramakrishna, V. & Champion, B. Antibody-targeted vaccines. Oncogene 26, 3758–3767 (2007).10.1038/sj.onc.1210375 ↗
50. Bonifaz, L. C. et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199, 815–824 (2004).10.1084/jem.20032220 ↗
51. Kretschmer, K. et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6, 1219–1227 (2005).10.1038/ni1265 ↗
52. Jiang, W. et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375, 151–155 (1995).10.1038/375151a0 ↗
53. Klechevsky, E. et al. Understanding human myeloid dendritic cell subsets for the rational design of novel vaccines. Hum. Immunol. 70, 281–288 (2009).10.1016/j.humimm.2009.02.004 ↗
54. Klechevsky, E. et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 29, 497–510 (2008).10.1016/j.immuni.2008.07.013 ↗
55. Liu, J., Geng, X., Hou, J. & Wu, G. New insights into M1/M2 macrophages: key modulators in cancer progression. Cancer Cell Int. 21, 389 (2021).10.1186/s12935-021-02089-2 ↗
56. Chen, S. et al. Macrophages in immunoregulation and therapeutics. Signal. Transduct. Target. Ther. 8, 207 (2023).10.1038/s41392-023-01452-1 ↗
57. Wang, N., Liang, H. & Zen, K. Molecular mechanisms that influence the macrophage M1–M2 polarization balance. Front. Immunol. 5, 614 (2014).10.3389/fimmu.2014.00614 ↗
58. Mukhtar, M. et al. Drug delivery to macrophages: a review of nano-therapeutics targeted approach for inflammatory disorders and cancer. Expert. Opin. Drug Deliv. 17, 1239–1257 (2020).10.1080/17425247.2020.1783237 ↗
59. Yang, D. et al. A sweet spot for macrophages: focusing on polarization. Pharmacol. Res. 167, 105576 (2021).10.1016/j.phrs.2021.105576 ↗
60. Li, X. et al. β-glucan, a dectin-1 ligand, promotes macrophage M1 polarization via NF-κB/autophagy pathway. Int. J. Oncol. 54, 271–282 (2019).
61. Zhu, W. et al. Zoledronic acid promotes TLR‐4‐mediated M1 macrophage polarization in bisphosphonate‐related osteonecrosis of the jaw. FASEB J. 33, 5208–5219 (2019).10.1096/fj.201801791RR ↗
62. Chen, L. et al. NF-κB p65 and SETDB1 expedite lipopolysaccharide-induced intestinal inflammation in mice by inducing IRF7/NLR-dependent macrophage M1 polarization. Int. Immunopharmacol. 115, 109554 (2023).10.1016/j.intimp.2022.109554 ↗
63. Kalia, N., Singh, J. & Kaur, M. The role of dectin-1 in health and disease. Immunobiology 226, 152071 (2021).10.1016/j.imbio.2021.152071 ↗
64. Rőszer, T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015, 816460 (2015).10.1155/2015/816460 ↗
65. Dambuza, I. M. & Brown, G. D. C-type lectins in immunity: recent developments. Curr. Opin. Immunol. 32, 21–27 (2015).10.1016/j.coi.2014.12.002 ↗
66. Lefèvre, L. et al. PPARγ ligands switched high fat diet-induced macrophage M2b polarization toward M2a thereby improving intestinal Candida elimination. PLoS One 5, e12828 (2010).10.1371/journal.pone.0012828 ↗
67. Reid, D. M. et al. Expression of the beta-glucan receptor, Dectin-1, on murine leukocytes in situ correlates with its function in pathogen recognition and reveals potential roles in leukocyte interactions. J. Leukoc. Biol. 76, 86–94 (2004).10.1189/jlb.0104031 ↗
68. Herre, J., Gordon, S. & Brown, G. D. Dectin-1 and its role in the recognition of beta-glucans by macrophages. Mol. Immunol. 40, 869–876 (2004).10.1016/j.molimm.2003.10.007 ↗
69. Loures, F. V. et al. Dectin-1 induces M1 macrophages and prominent expansion of CD8+IL-17+ cells in pulmonary paracoccidioidomycosis. J. Infect. Dis. 210, 762–773 (2014).10.1093/infdis/jiu136 ↗
70. Haase, J. et al. Local proliferation of macrophages in adipose tissue during obesity-induced inflammation. Diabetologia 57, 562–571 (2014).10.1007/s00125-013-3139-y ↗
71. Dupasquier, M. et al. The dermal microenvironment induces the expression of the alternative activation marker CD301/mMGL in mononuclear phagocytes, independent of IL-4/IL-13 signaling. J. Leukoc. Biol. 80, 838–849 (2006).10.1189/jlb.1005564 ↗
72. Kambara, K. et al. In vivo depletion of CD206+ M2 macrophages exaggerates lung injury in endotoxemic mice. Am. J. Pathol. 185, 162–171 (2015).10.1016/j.ajpath.2014.09.005 ↗
73. Medbury, H. J. et al. Differing association of macrophage subsets with atherosclerotic plaque stability. Int. Angiol. 32, 74–84 (2013).
74. Rivollier, A., He, J., Kole, A., Valatas, V. & Kelsall, B. L. Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J. Exp. Med. 209, 139–155 (2012).10.1084/jem.20101387 ↗
75. Xisto, M. I. D. d. S. et al. An α-glucan from Lomentospora prolificans mediates fungal–host interaction signaling through Dectin-1 and Mincle. J. Fungi 9, 291 (2023).10.3390/jof9030291 ↗
76. Zhang, P., Liu, W., Peng, Y., Han, B. & Yang, Y. Toll like receptor 4 (TLR4) mediates the stimulating activities of chitosan oligosaccharide on macrophages. Int. Immunopharmacol 23, 254–261 (2014).10.1016/j.intimp.2014.09.007 ↗
77. Da Silva, C. A., Hartl, D., Liu, W., Lee, C. G. & Elias, J. A. TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation. J. Immunol. 181, 4279–4286 (2008).10.4049/jimmunol.181.6.4279 ↗
78. Wang, H.-Y. et al. Dendrobium officinale polysaccharide promotes M1 polarization of TAMs to inhibit tumor growth by targeting TLR2. Carbohydr. Polym. 292, 119683 (2022).10.1016/j.carbpol.2022.119683 ↗
79. Vidyarthi, A. et al. TLR-3 stimulation skews M2 macrophages to M1 through IFN-αβ signaling and restricts tumor progression. Front. Immunol. 9, 1650 (2018).10.3389/fimmu.2018.01650 ↗
80. Wanderley, C. W. et al. Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner. Cancer Res. 78, 5891–5900 (2018).10.1158/0008-5472.CAN-17-3480 ↗
81. Tiwari, R. K. et al. Repolarization of glioblastoma macrophage cells using non-agonistic Dectin-1 ligand encapsulating TLR-9 agonist: plausible role in regenerative medicine against brain tumor. Int. J. Neurosci. 131, 591–598 (2021).10.1080/00207454.2020.1750393 ↗
82. Zhan, X. et al. Targeted depletion of tumour-associated macrophages by an alendronate–glucomannan conjugate for cancer immunotherapy. Biomaterials 35, 10046–10057 (2014).10.1016/j.biomaterials.2014.09.007 ↗
83. Plavcová, Z. et al. Curcumin encapsulation in yeast glucan particles promotes its anti-inflammatory potential in vitro. Int. J. Pharm. 568, 118532 (2019).10.1016/j.ijpharm.2019.118532 ↗
84. Coico, R. Immunology: A Short Course (Wiley, 2021).
85. Sahasrabudhe, N. M., Dokter-Fokkens, J. & de Vos, P. Particulate β-glucans synergistically activate TLR4 and Dectin-1 in human dendritic cells. Mol. Nutr. Food Res. 60, 2514–2522 (2016).10.1002/mnfr.201600356 ↗
86. Son, S. et al. Sugar-nanocapsules imprinted with microbial molecular patterns for mRNA vaccination. Nano Lett. 20, 1499–1509 (2020).10.1021/acs.nanolett.9b03483 ↗
87. Son, S. et al. Induction of T-helper-17-cell-mediated anti-tumour immunity by pathogen-mimicking polymer nanoparticles. Nat. Biomed. Eng. 7, 72–84 (2023).10.1038/s41551-022-00973-4 ↗
88. Yin, M., Zhang, Y. & Li, H. Advances in research on immunoregulation of macrophages by plant polysaccharides. Front. Immunol. 10, 145 (2019).10.3389/fimmu.2019.00145 ↗
89. Han, B., Baruah, K., Cox, E., Vanrompay, D. & Bossier, P. Structure-functional activity relationship of β-glucans from the perspective of immunomodulation: a mini-review. Front. Immunol. 11, 658 (2020).10.3389/fimmu.2020.00658 ↗
90. Adachi, Y., Ohno, N., Ohsawa, M., Oikawa, S. & Yadomae, T. Change of biological activities of (1→ 3)-β-d-glucan from Grifola frondosa upon molecular weight reduction by heat treatment. Chem. Pharm. Bull. 38, 477–481 (1990).10.1248/cpb.38.477 ↗
91. Sletmoen, M. & Stokke, B. T. Higher order structure of (1,3)-β-d-glucans and its influence on their biological activities and complexation abilities. Biopolymers 89, 310–321 (2008).10.1002/bip.20920 ↗
92. Brown, G. D. & Gordon, S. Fungal β-glucans and mammalian immunity. Immunity 19, 311–315 (2003).10.1016/S1074-7613(03)00233-4 ↗
93. Bohn, J. A. & BeMiller, J. N. (1→3)-β-D-Glucans as biological response modifiers: a review of structure–functional activity relationships. Carbohydr. Polym. 28, 3–14 (1995).10.1016/0144-8617(95)00076-3 ↗
94. Ogawa, T. & Kasuragi, T. Synthesis of a branched d-glucotetraose, the repeating unit of the extracellular polysaccharides of Grifola umbellate, Sclerotinia libertiana, Porodisculus pendulus, and Schizophyllum commune Fries. Carbohydr. Res. 103, 53–64 (1982).10.1016/S0008-6215(82)80007-4 ↗
95. Lei, N. et al. Effects of low molecular weight yeast β-glucan on antioxidant and immunological activities in mice. Int. J. Mol. Sci. 16, 21575–21590 (2015).10.3390/ijms160921575 ↗
96. Li, S. et al. Molecular modification of polysaccharides and resulting bioactivities. Compr. Rev. Food Sci. Food Saf. 15, 237–250 (2016).10.1111/1541-4337.12161 ↗
97. Bertholon, I., Vauthier, C. & Labarre, D. Complement activation by core–shell poly (isobutylcyanoacrylate)–polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm. Res. 23, 1313–1323, (2006).10.1007/s11095-006-0069-0 ↗
98. Yu, K. et al. Modulation of complement activation and amplification on nanoparticle surfaces by glycopolymer conformation and chemistry. ACS Nano 8, 7687–7703 (2014).10.1021/nn504186b ↗
99. Toufik, J. & Labarre, D. Relationship between reduction of complement activation by polysaccharide surfaces bearing diethylaminoethyl groups and their degree of substitution. Biomaterials 16, 1081–1088 (1995).10.1016/0142-9612(95)98904-S ↗
100. Tao, Y. et al. Carboxymethylated hyperbranched polysaccharide: synthesis, solution properties, and fabrication of hydrogel. Carbohydr. Polym. 128, 179–187 (2015).10.1016/j.carbpol.2015.04.012 ↗